Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of
| Condition(s) | Peripheral Vascular Diseases |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature. |
| Who can participate | Inclusion Criteria: * Patients 18 years and older * Written informed consent (patient data release-form) * Use of any commercially available Boston Scientific drug-eluting device marketed for treatment of lesions in the peripheral vasculature and specified in the Registry Enrollment Guide Exclusion Criteria: * Life expectancy of \<1 year |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Boston Scientific Corporation |
| Locations | Jonesboro, Arkansas, United States; Los Angeles, California, United States; Los Angeles, California, United States; Los Angeles, California, United States; Sacramento, California, United States; St. Helena, California, United States (+73 more sites) |
| Start date | 2021-03-29 |
| NCT ID | NCT04674969 |
| Official listing | https://clinicaltrials.gov/study/NCT04674969 |